You are viewing the site in preview mode
Skip to main content
| | |
Placebo
|
ARB
|
|---|
| | |
(n = 40)
|
(n = 41)
|
|
Demographics
|
|
Age
|
years
|
62 ± 14
|
61 ± 16
|
|
Gender (males)
|
n (%)
|
25 (63)
|
30 (73)
|
|
Body weight
|
kg
|
81 ± 17
|
79 ± 17
|
|
Body mass index
|
kg/m2
|
27 ± 5
|
26 ± 5
|
|
Diabetes
|
n (%)
|
12 (30)
|
13 (32)
|
|
Heart disease
|
n (%)
|
17 (43)
|
15 (37)
|
|
Ischemic heart disease
|
n (%)
|
9 (23)
|
8 (20)
|
|
Charlson co-morbidity index
| |
3.5 ± 1.6
|
3.8 ± 1.9
|
|
LV mass index
|
g/m2
|
126 ± 36
|
126 ± 33
|
|
LV EF
|
%
|
60 ± 9
|
62 ± 9
|
|
Cardiac medications
|
|
Aspirin treatment
|
n (%)
|
21 (51)
|
16 (39)
|
|
Antiplatelet (non-aspirin) drugs
|
n (%)
|
3 (7)
|
3 (7)
|
|
Statin treatment
|
n (%)
|
21 (51)
|
15 (37)
|
|
Nitrate medication
|
n (%)
|
6 (14)
|
4 (10)
|
|
BP and BP-medication
|
|
Baseline systolic BP (preHD)
|
mmHg
|
145 ± 19
|
148 ± 21
|
|
Baseline diastolic BP (preHD)
|
mmHg
|
72 ± 12
|
76 ± 13
|
|
12 month systolic BP (preHD)
|
mmHg
|
136 ± 22
|
138 ± 20
|
|
12 month diastolic BP (preHD)
|
mmHg
|
68 ± 15
|
69 ± 11
|
|
BP-drugs excl. Placebo/ARB
|
n
|
2.6 ± 1.0
|
2.5 ± 0.9
|
|
BP-drugs excl. Placebo/ARB
|
DDD
|
1.8 ± 1.3
|
1.8 ± 1.2
|
|
Dialysis parameters
|
|
Time on dialysis
|
days
|
141 (53–431)
|
148 (54–400)
|
|
AV-fistula/central catheter
|
n (%)
|
35 (88)/5 (12)
|
32 (78)/9 (22)
|
|
Urine output
|
L/24 h
|
1.3 ± 0.7
|
1.4 ± 0.8
|
|
Glomerular filtration rate
|
mL/min/1.73 m2
|
4.8 ± 2.3
|
5.7 ± 3.3
|
|
Frequency
|
times/week
|
3 (2–3)
|
3 (2–4)
|
|
HD-time
|
hours/week
|
10 ± 2
|
11 ± 3
|
|
Ultrafiltration
|
L
|
1.2 (0–4.3)
|
0.5 (0–3.8)
|
|
Urea reduction ratio
|
%
|
64 ± 8
|
62 ± 9
|
|
Hematocrit (EVF)
| |
0.33 ± 0.05
|
0.34 ± 0.04
|
- Heart disease included various conditions such as ischemic heart disease, mild heart failure (LV EF > 30%) and valvulopathy. Ischemic heart disease was defined by the presence of known ischemic heart disease, angina, pre-trial myocardial infarction, and pre-trial PCI or CABG treatment. LV Left ventricular; EF Ejection fraction; BP Blood pressure; preHD Pre-hemodialysis; DDD Defined daily doses; EVF Erythrocyte volume fraction
